Sinovac Biotech Ltd. said its main operating entity, Sinovac Beijing, was named to the Deloitte Technology Fast 50 China 2008. A vaccine maker, Sinovac’s revenues derive mainly from its hepatitis A vaccine, Healive™. The company also makes a combination hepatitis A & B vaccine, a flu vaccine and an avian flu vaccine. Sinovac said it was put on the list because of its 290% growth rate over the past three years. More details...

Stock Symbol: (AMEX: SVA)